Good morning :)
Place Order
Add to Watchlist

Shukra Pharmaceuticals Ltd

SHUKRAPHAR

Shukra Pharmaceuticals Ltd

SHUKRAPHAR
Health CarePharmaceuticals
SmallcapWith a market cap of ₹289 cr, stock is ranked 2,202
High RiskStock is 3.64x as volatile as Nifty
67.181.19% (-0.81)
67.181.19% (-0.81)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹289 cr, stock is ranked 2,202
High RiskStock is 3.64x as volatile as Nifty
Scorecard

Performance

High

The creamy layer - amongst the top performing stocks

Valuation

High

Seems to be overvalued vs the market average

Growth

High

Strong financials and growth story over the years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹289 cr, stock is ranked 2,202
High RiskStock is 3.64x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
15.565.020.38%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.276.550.51%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Shukra Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceuticals Products.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 68.49%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0% to 0.02%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 109.47%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue5.015.215.485.7011.9511.5620.5760.0377.3960.49
Raw Materialssubtract1.640.950.891.163.332.9611.0845.6543.7837.72
Power & Fuel Costsubtract0.260.260.290.341.641.780.000.000.00
Employee Costsubtract1.131.051.231.914.343.754.574.415.02
Selling & Administrative Expensessubtract0.440.921.200.711.211.362.443.385.15
Operating & Other expensessubtract0.750.490.15-0.11-0.210.10-0.490.031.21
Depreciation/Amortizationsubtract0.450.470.740.961.481.471.661.842.052.26
Interest & Other Itemssubtract0.000.010.040.000.000.030.290.280.290.26
Taxes & Other Itemssubtract0.230.550.420.270.14-0.090.270.041.341.65
EPS0.040.170.170.150.010.070.252.427.404.24
DPS0.000.030.030.030.000.000.030.130.250.13
Payout ratio0.000.150.150.170.000.000.100.050.030.03

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Shukra Pharmaceuticals Ltd15.605.020.38%
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare SHUKRAPHAR with any stock or ETF
Compare SHUKRAPHAR with any stock or ETF
SHUKRAPHAR
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding50.96%0.00%0.11%0.00%48.93%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

AugSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 23, 2024

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 23, 2024

Cash Dividend

Ex DateEx DateSep 15, 2023

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 15, 2023

Cash Dividend

Ex DateEx DateSep 22, 2022

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 22, 2022

Cash Dividend

Ex DateEx DateSep 19, 2019

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 19, 2019

Cash Dividend

Ex DateEx DateAug 31, 2018

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Aug 31, 2018

News & Opinions
Corporate
Shukra Pharmaceuticals to discuss results

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

8 hours agoCapital Market - Live
Corporate
Shukra Pharmaceuticals schedules board meeting

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Shukra Pharmaceuticals to hold AGM

Shukra Pharmaceuticals announced that the 31th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Shukra Pharmaceuticals standalone net profit rises 16.67% in the June 2024 quarter

Net profit of Shukra Pharmaceuticals rose 16.67% to Rs 0.49 crore in the quarter ended June 2024 as against Rs 0.42 crore during the previous quarter ended June 2023. Sales declined 84.23% to Rs 3.18 crore in the quarter ended June 2024 as against Rs 20.16 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales3.1820.16 -84 OPM %25.791.69 - PBDT1.480.89 66 PBT0.810.43 88 NP0.490.42 17 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Shukra Pharmaceuticals to discuss results

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Shukra Pharmaceuticals schedules EGM

Shukra Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 23 August 2024 .Powered by Capital Market - Live

3 months agoCapital Market - Live

Crorepati stocks! How these 12 tiny stocks turned Rs 1 lakh to up to Rs 2 crore

1 year agoBusiness Today

Given multibagger return YTD, this pharma stock fixes record date for dividend

2 years agoLivemint

Shukra Pharmaceuticals board approves rights issue worth Rs19 crore; Stock climbs 3.4%

2 years agoIndia Infoline

Shukra Pharmaceuticals standalone net profit declines 76.19% in the December 2021 quarter

2 years agoBusiness Standard